Suppr超能文献

评估乳腺癌中HER2检测质量:来自德国一项大型多中心观察性研究中影响HER2阳性率的变量

Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany.

作者信息

Rüschoff Josef, Lebeau Annette, Kreipe Hans, Sinn Peter, Gerharz Claus Dieter, Koch Winfried, Morris Stefanie, Ammann Johannes, Untch Michael

机构信息

Institut für Pathologie Nordhessen and Targos Molecular Pathology GmbH, Kassel, Germany.

Institut für Pathologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Gemeinschaftspraxis für Pathologie, Lübeck, Germany.

出版信息

Mod Pathol. 2017 Feb;30(2):217-226. doi: 10.1038/modpathol.2016.164. Epub 2016 Oct 21.

Abstract

Despite >10 years of routine human epidermal growth factor receptor 2 (HER2) testing in breast cancer, testing quality is still an issue. Guidelines recommend assessing HER2 positivity rates as a quality indicator; however, the extent to which patient- or tumor-related factors influence HER2 positivity is still unknown. The present study analyzed these influences to identify pathology centers with HER2 positivity rates unexplained by patient- or tumor-related factors. This observational, prospective study monitored routine HER2 testing at 57 institutes of pathology in Germany (January 2013-August 2014). Data collected included HER2 test result, patient- and tumor-related factors, sample source, and method of sample retrieval. Factors influencing HER2 positivity rates were identified by multiple logistic regression. Individual center effects were assessed in an extended multiple logistic regression model by their statistical significance after adjusting for the combined effect of patient- or tumor-related covariates and multiple testing. Analyses included 15 332 invasive breast cancer samples. Histologic grade showed the strongest influence on HER2 positivity, followed by hormone receptor status, histologic subtype, age, and nodal status (all P<0.0001). The overall HER2 positivity rate across centers was 14.4% (range 7.1-27.3%). A statistically significant center effect on the HER2 positivity rate was identified for three centers (P<0.05), with a trend toward a center effect for a further three (P<0.2). This study, the first of its kind, highlights that assessing HER2 testing quality with HER2 positivity rates should include standardized assessment of patient- or tumor-related characteristics to identify centers with HER2 testing quality issues more effectively. As treatment options for HER2-positive breast cancer continue to evolve, identifying the right patients is key.

摘要

尽管在乳腺癌中进行常规人类表皮生长因子受体2(HER2)检测已有10多年,但检测质量仍是一个问题。指南建议将评估HER2阳性率作为一项质量指标;然而,患者或肿瘤相关因素对HER2阳性的影响程度仍不清楚。本研究分析了这些影响因素,以确定HER2阳性率无法用患者或肿瘤相关因素解释的病理中心。这项观察性前瞻性研究监测了德国57家病理研究所的常规HER2检测(2013年1月至2014年8月)。收集的数据包括HER2检测结果、患者和肿瘤相关因素、样本来源以及样本获取方法。通过多因素logistic回归确定影响HER2阳性率的因素。在扩展的多因素logistic回归模型中,通过调整患者或肿瘤相关协变量和多次检测的综合效应后,根据其统计学意义评估各个中心的效应。分析包括15332例浸润性乳腺癌样本。组织学分级对HER2阳性的影响最强,其次是激素受体状态、组织学亚型、年龄和淋巴结状态(均P<0.0001)。各中心的总体HER2阳性率为14.4%(范围7.1%-27.3%)。确定有三个中心对HER2阳性率有统计学显著的中心效应(P<0.05),另外三个中心有中心效应的趋势(P<0.2)。本研究属同类研究中的首例,强调用HER2阳性率评估HER2检测质量应包括对患者或肿瘤相关特征的标准化评估,以便更有效地识别存在HER2检测质量问题的中心。随着HER2阳性乳腺癌的治疗选择不断发展,确定合适的患者是关键。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验